You are here

  • Home
  • Archive
  • Volume 8, Issue 2
  • Clinical activity of pembrolizumab in metastatic prostate cancer with microsatellite instability high (MSI-H) detected by circulating tumor DNA

Article metrics

Article menu

Download PDFPDF

XML
Clinical/translational cancer immunotherapy
Short report
Clinical activity of pembrolizumab in metastatic prostate cancer with microsatellite instability high (MSI-H) detected by circulating tumor DNA

 

Online download statistics by month:

Online download statistics by month: August 2020 to May 2023

AbstractFullPdf
Aug 2020947947222
Sep 2020550550183
Oct 202030030194
Nov 202021521477
Dec 202024924986
Jan 202122422458
Feb 202125725788
Mar 202138338395
Apr 202131431490
May 202125525562
Jun 202122622661
Jul 202118518663
Aug 202117517555
Sep 202117417459
Oct 202118918955
Nov 202118318364
Dec 202118418556
Jan 202216616962
Feb 202216016758
Mar 202214014256
Apr 202214414862
May 202213013375
Jun 202214414553
Jul 202214015052
Aug 202215415441
Sep 202220020265
Oct 202214414790
Nov 202212412542
Dec 202211911943
Jan 202310510843
Feb 202312212530
Mar 202317617844
Apr 2023919133
May 202312712735
Total739674422352